| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spectrometry, Fluorescence | 14 | 2023 | 184 | 4.570 |
Why?
|
| Skin Neoplasms | 28 | 2023 | 178 | 4.000 |
Why?
|
| Spectrum Analysis, Raman | 8 | 2021 | 95 | 2.820 |
Why?
|
| Tryptophan | 10 | 2019 | 66 | 2.470 |
Why?
|
| Brain | 8 | 2026 | 1472 | 2.150 |
Why?
|
| Dermoscopy | 22 | 2020 | 22 | 2.090 |
Why?
|
| Breast Neoplasms | 10 | 2023 | 1723 | 1.880 |
Why?
|
| Melanoma | 14 | 2023 | 110 | 1.820 |
Why?
|
| NAD | 8 | 2017 | 45 | 1.730 |
Why?
|
| Prostatic Neoplasms | 8 | 2023 | 1092 | 1.580 |
Why?
|
| Spectroscopy, Near-Infrared | 4 | 2017 | 25 | 1.390 |
Why?
|
| Collagen | 10 | 2024 | 181 | 1.330 |
Why?
|
| Optical Phenomena | 4 | 2026 | 19 | 1.300 |
Why?
|
| Lasers | 7 | 2024 | 57 | 1.290 |
Why?
|
| Humans | 100 | 2026 | 43102 | 1.110 |
Why?
|
| Infrared Rays | 3 | 2017 | 21 | 1.050 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2014 | 174 | 0.990 |
Why?
|
| Spectrum Analysis | 1 | 2026 | 61 | 0.940 |
Why?
|
| Molecular Imaging | 2 | 2016 | 30 | 0.900 |
Why?
|
| Skin | 10 | 2023 | 187 | 0.890 |
Why?
|
| Breast | 4 | 2019 | 139 | 0.890 |
Why?
|
| Carotenoids | 3 | 2020 | 74 | 0.880 |
Why?
|
| Brain Neoplasms | 2 | 2019 | 140 | 0.870 |
Why?
|
| Psoriasis | 6 | 2022 | 19 | 0.870 |
Why?
|
| Alzheimer Disease | 2 | 2026 | 1001 | 0.850 |
Why?
|
| Welding | 1 | 2024 | 1 | 0.850 |
Why?
|
| Laser Therapy | 2 | 2015 | 25 | 0.830 |
Why?
|
| Refractometry | 1 | 2023 | 16 | 0.810 |
Why?
|
| Meningeal Neoplasms | 2 | 2021 | 5 | 0.810 |
Why?
|
| Meningioma | 2 | 2021 | 7 | 0.810 |
Why?
|
| Uterine Cervical Dysplasia | 2 | 2014 | 43 | 0.800 |
Why?
|
| Scattering, Radiation | 4 | 2017 | 43 | 0.780 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2014 | 58 | 0.780 |
Why?
|
| Prostate | 2 | 2023 | 155 | 0.760 |
Why?
|
| Diagnostic Imaging | 2 | 2013 | 53 | 0.720 |
Why?
|
| Antineoplastic Agents | 6 | 2021 | 1019 | 0.710 |
Why?
|
| Principal Component Analysis | 6 | 2021 | 87 | 0.700 |
Why?
|
| Female | 42 | 2026 | 24698 | 0.680 |
Why?
|
| Photosynthesis | 1 | 2021 | 35 | 0.670 |
Why?
|
| Algorithms | 6 | 2023 | 509 | 0.650 |
Why?
|
| Acetone | 1 | 2020 | 7 | 0.640 |
Why?
|
| Methanol | 1 | 2020 | 22 | 0.630 |
Why?
|
| Animals | 18 | 2024 | 16992 | 0.630 |
Why?
|
| Microscopy, Fluorescence | 3 | 2017 | 256 | 0.620 |
Why?
|
| Microscopy, Confocal | 4 | 2020 | 224 | 0.620 |
Why?
|
| Photons | 2 | 2016 | 29 | 0.610 |
Why?
|
| Swine | 6 | 2024 | 212 | 0.600 |
Why?
|
| Chlorophyll | 2 | 2021 | 24 | 0.600 |
Why?
|
| Nanostructures | 1 | 2021 | 161 | 0.580 |
Why?
|
| Glioma | 1 | 2019 | 96 | 0.570 |
Why?
|
| Lymph Nodes | 2 | 2017 | 74 | 0.560 |
Why?
|
| Male | 36 | 2026 | 23409 | 0.550 |
Why?
|
| Flavin-Adenine Dinucleotide | 1 | 2017 | 5 | 0.530 |
Why?
|
| Aorta | 3 | 2016 | 198 | 0.530 |
Why?
|
| Dermatitis, Atopic | 3 | 2021 | 10 | 0.520 |
Why?
|
| Alopecia Areata | 3 | 2021 | 4 | 0.510 |
Why?
|
| MicroRNAs | 4 | 2024 | 518 | 0.510 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2014 | 66 | 0.500 |
Why?
|
| Dermatologic Agents | 3 | 2021 | 9 | 0.490 |
Why?
|
| Sensitivity and Specificity | 7 | 2023 | 611 | 0.480 |
Why?
|
| Pattern Recognition, Automated | 2 | 2014 | 32 | 0.470 |
Why?
|
| Tomography, Optical | 2 | 2012 | 2 | 0.470 |
Why?
|
| Tinea | 3 | 2020 | 8 | 0.460 |
Why?
|
| Lasers, Solid-State | 2 | 2011 | 12 | 0.450 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2014 | 18 | 0.440 |
Why?
|
| Wound Healing | 1 | 2015 | 88 | 0.440 |
Why?
|
| Models, Chemical | 2 | 2013 | 204 | 0.440 |
Why?
|
| Microvessels | 1 | 2014 | 31 | 0.440 |
Why?
|
| Spinacia oleracea | 1 | 2014 | 8 | 0.430 |
Why?
|
| Hashimoto Disease | 2 | 2024 | 2 | 0.420 |
Why?
|
| Lipoproteins, HDL | 1 | 2014 | 48 | 0.410 |
Why?
|
| Plant Leaves | 1 | 2014 | 136 | 0.410 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2020 | 186 | 0.400 |
Why?
|
| Aged | 17 | 2026 | 8214 | 0.400 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2014 | 160 | 0.400 |
Why?
|
| Ferric Compounds | 1 | 2014 | 62 | 0.400 |
Why?
|
| Crohn Disease | 2 | 2024 | 71 | 0.400 |
Why?
|
| Indocyanine Green | 1 | 2013 | 4 | 0.400 |
Why?
|
| Fluorescein | 1 | 2013 | 18 | 0.390 |
Why?
|
| Fluorescence Polarization | 1 | 2013 | 28 | 0.390 |
Why?
|
| Meat | 1 | 2013 | 46 | 0.380 |
Why?
|
| Carcinoma | 1 | 2013 | 108 | 0.370 |
Why?
|
| Diagnosis, Differential | 9 | 2019 | 238 | 0.360 |
Why?
|
| Colitis, Ulcerative | 2 | 2024 | 70 | 0.360 |
Why?
|
| Equipment Design | 3 | 2020 | 145 | 0.350 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2012 | 94 | 0.350 |
Why?
|
| Hidradenitis Suppurativa | 2 | 2021 | 3 | 0.350 |
Why?
|
| Terahertz Radiation | 1 | 2011 | 1 | 0.350 |
Why?
|
| Terahertz Spectroscopy | 1 | 2011 | 1 | 0.350 |
Why?
|
| Vibration | 2 | 2021 | 23 | 0.330 |
Why?
|
| Middle Aged | 18 | 2025 | 12222 | 0.320 |
Why?
|
| Treatment Outcome | 9 | 2023 | 1604 | 0.320 |
Why?
|
| Neoplasms | 4 | 2017 | 1377 | 0.320 |
Why?
|
| Chickens | 3 | 2017 | 161 | 0.310 |
Why?
|
| Sarcoma, Kaposi | 2 | 2021 | 23 | 0.310 |
Why?
|
| Lipids | 3 | 2017 | 256 | 0.310 |
Why?
|
| Nail Diseases | 2 | 2019 | 3 | 0.310 |
Why?
|
| Nevus, Pigmented | 2 | 2020 | 6 | 0.300 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2013 | 367 | 0.290 |
Why?
|
| ROC Curve | 3 | 2013 | 159 | 0.280 |
Why?
|
| Light | 2 | 2024 | 185 | 0.280 |
Why?
|
| Elastin | 3 | 2013 | 40 | 0.280 |
Why?
|
| Histiocytoma, Benign Fibrous | 2 | 2019 | 5 | 0.280 |
Why?
|
| Nanoparticles | 1 | 2014 | 460 | 0.280 |
Why?
|
| Biopsy | 3 | 2023 | 177 | 0.260 |
Why?
|
| Reproducibility of Results | 5 | 2015 | 1081 | 0.260 |
Why?
|
| Multivariate Analysis | 3 | 2013 | 638 | 0.260 |
Why?
|
| Mice | 5 | 2023 | 6644 | 0.250 |
Why?
|
| Keratosis, Actinic | 2 | 2023 | 4 | 0.240 |
Why?
|
| Thyroid Neoplasms | 2 | 2023 | 50 | 0.240 |
Why?
|
| Aged, 80 and over | 8 | 2025 | 2853 | 0.240 |
Why?
|
| Fourier Analysis | 3 | 2014 | 45 | 0.230 |
Why?
|
| Adult | 16 | 2025 | 13872 | 0.230 |
Why?
|
| Optics and Photonics | 2 | 2017 | 34 | 0.230 |
Why?
|
| Dermatology | 2 | 2022 | 3 | 0.220 |
Why?
|
| Retrospective Studies | 10 | 2020 | 2544 | 0.220 |
Why?
|
| Thyroid Nodule | 2 | 2023 | 4 | 0.210 |
Why?
|
| West Nile Fever | 1 | 2025 | 68 | 0.210 |
Why?
|
| Fluorescent Dyes | 3 | 2014 | 182 | 0.210 |
Why?
|
| West Nile virus | 1 | 2025 | 78 | 0.210 |
Why?
|
| Disease Outbreaks | 1 | 2025 | 175 | 0.210 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2024 | 97 | 0.200 |
Why?
|
| Spores, Bacterial | 1 | 2003 | 9 | 0.200 |
Why?
|
| Starvation | 1 | 2003 | 12 | 0.200 |
Why?
|
| Picolinic Acids | 1 | 2003 | 12 | 0.200 |
Why?
|
| Photochemotherapy | 1 | 2023 | 43 | 0.200 |
Why?
|
| Bacillus subtilis | 1 | 2003 | 15 | 0.200 |
Why?
|
| Klinefelter Syndrome | 1 | 2023 | 3 | 0.200 |
Why?
|
| Thyroid Diseases | 1 | 2023 | 6 | 0.200 |
Why?
|
| Vitreous Body | 1 | 2003 | 10 | 0.200 |
Why?
|
| Sodium Glutamate | 1 | 2003 | 5 | 0.200 |
Why?
|
| Rats | 3 | 2016 | 3735 | 0.200 |
Why?
|
| Scalp | 2 | 2023 | 12 | 0.200 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 11 | 0.200 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2023 | 24 | 0.200 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 21 | 0.200 |
Why?
|
| Dinitrocresols | 2 | 2013 | 2 | 0.200 |
Why?
|
| Pilot Projects | 4 | 2024 | 760 | 0.200 |
Why?
|
| Area Under Curve | 2 | 2013 | 95 | 0.190 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2024 | 104 | 0.190 |
Why?
|
| Eye | 1 | 2003 | 77 | 0.190 |
Why?
|
| Hippocampus | 1 | 2026 | 594 | 0.190 |
Why?
|
| Pulmonary Fibrosis | 1 | 2022 | 38 | 0.180 |
Why?
|
| Pigmentation Disorders | 2 | 2018 | 3 | 0.180 |
Why?
|
| Staphylococcus aureus | 1 | 2003 | 94 | 0.180 |
Why?
|
| Dermatitis, Perioral | 1 | 2021 | 1 | 0.180 |
Why?
|
| Diabetic Retinopathy | 1 | 2003 | 78 | 0.180 |
Why?
|
| Vitis | 1 | 2022 | 37 | 0.180 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2021 | 10 | 0.180 |
Why?
|
| Glaucoma | 1 | 2003 | 100 | 0.180 |
Why?
|
| Water | 1 | 2024 | 316 | 0.180 |
Why?
|
| Liver Diseases | 1 | 2021 | 34 | 0.180 |
Why?
|
| Docosahexaenoic Acids | 1 | 2021 | 19 | 0.170 |
Why?
|
| Photosystem I Protein Complex | 1 | 2021 | 2 | 0.170 |
Why?
|
| Time Factors | 1 | 2026 | 1857 | 0.170 |
Why?
|
| Anilides | 1 | 2021 | 28 | 0.170 |
Why?
|
| Acquired Hyperostosis Syndrome | 1 | 2021 | 2 | 0.170 |
Why?
|
| Gastrointestinal Agents | 1 | 2021 | 6 | 0.170 |
Why?
|
| Facial Neoplasms | 2 | 2017 | 5 | 0.170 |
Why?
|
| Nevus | 2 | 2020 | 5 | 0.170 |
Why?
|
| Hot Temperature | 2 | 2011 | 141 | 0.170 |
Why?
|
| Biphenyl Compounds | 1 | 2021 | 53 | 0.170 |
Why?
|
| Molluscum Contagiosum | 1 | 2020 | 2 | 0.170 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2021 | 384 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 220 | 0.170 |
Why?
|
| Skin Diseases, Papulosquamous | 1 | 2020 | 1 | 0.160 |
Why?
|
| Lichens | 1 | 2020 | 2 | 0.160 |
Why?
|
| Keratosis | 1 | 2020 | 4 | 0.160 |
Why?
|
| Herpes Zoster | 1 | 2020 | 12 | 0.160 |
Why?
|
| Pyridines | 1 | 2021 | 139 | 0.160 |
Why?
|
| Pityriasis Rubra Pilaris | 1 | 2019 | 1 | 0.160 |
Why?
|
| Child | 7 | 2023 | 3443 | 0.160 |
Why?
|
| Burning Mouth Syndrome | 1 | 2019 | 1 | 0.160 |
Why?
|
| Diabetes Complications | 1 | 2020 | 102 | 0.160 |
Why?
|
| Hypopigmentation | 1 | 2019 | 1 | 0.160 |
Why?
|
| Warts | 1 | 2019 | 5 | 0.150 |
Why?
|
| Hodgkin Disease | 1 | 2019 | 13 | 0.150 |
Why?
|
| Acantholysis | 1 | 2019 | 2 | 0.150 |
Why?
|
| Blood Transfusion | 1 | 2019 | 31 | 0.150 |
Why?
|
| Scalp Dermatoses | 1 | 2019 | 1 | 0.150 |
Why?
|
| Lichen Planus | 1 | 2019 | 5 | 0.150 |
Why?
|
| Mycosis Fungoides | 1 | 2019 | 2 | 0.150 |
Why?
|
| Trichophyton | 1 | 2019 | 5 | 0.150 |
Why?
|
| Hyperpigmentation | 1 | 2019 | 10 | 0.150 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 21 | 0.150 |
Why?
|
| Epigenesis, Genetic | 2 | 2021 | 291 | 0.150 |
Why?
|
| Irritants | 1 | 2019 | 8 | 0.150 |
Why?
|
| Nevus, Blue | 1 | 2019 | 2 | 0.150 |
Why?
|
| Forearm | 1 | 2019 | 5 | 0.150 |
Why?
|
| Catheter Ablation | 1 | 2019 | 34 | 0.150 |
Why?
|
| Sex Characteristics | 1 | 2021 | 258 | 0.150 |
Why?
|
| Granuloma | 1 | 2019 | 24 | 0.150 |
Why?
|
| Bowen's Disease | 1 | 2018 | 4 | 0.150 |
Why?
|
| Toes | 1 | 2018 | 6 | 0.150 |
Why?
|
| Protein Structure, Secondary | 1 | 2019 | 182 | 0.150 |
Why?
|
| Fluorescence | 2 | 2013 | 118 | 0.150 |
Why?
|
| Arthrodermataceae | 1 | 2018 | 1 | 0.150 |
Why?
|
| Hutchinson's Melanotic Freckle | 1 | 2018 | 1 | 0.150 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2018 | 2 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 179 | 0.150 |
Why?
|
| Immunotherapy | 2 | 2017 | 144 | 0.150 |
Why?
|
| Hemangioma, Capillary | 1 | 2018 | 2 | 0.140 |
Why?
|
| Angiokeratoma | 1 | 2018 | 2 | 0.140 |
Why?
|
| Skin Diseases, Vascular | 1 | 2018 | 4 | 0.140 |
Why?
|
| Case-Control Studies | 3 | 2020 | 1285 | 0.140 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2018 | 10 | 0.140 |
Why?
|
| Retina | 1 | 2021 | 289 | 0.140 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2018 | 12 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 146 | 0.140 |
Why?
|
| Models, Theoretical | 1 | 2020 | 232 | 0.140 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 148 | 0.140 |
Why?
|
| Proteomics | 2 | 2022 | 378 | 0.140 |
Why?
|
| Tyrosine | 2 | 2021 | 120 | 0.140 |
Why?
|
| Cell Line, Tumor | 3 | 2014 | 2676 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 1 | 2018 | 81 | 0.140 |
Why?
|
| Heart Failure | 1 | 2021 | 302 | 0.140 |
Why?
|
| Italy | 3 | 2025 | 27 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 259 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2018 | 92 | 0.130 |
Why?
|
| Dysplastic Nevus Syndrome | 1 | 2017 | 2 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 49 | 0.130 |
Why?
|
| Melanocytes | 1 | 2017 | 7 | 0.130 |
Why?
|
| Early Diagnosis | 1 | 2017 | 68 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 27 | 0.130 |
Why?
|
| Aminoquinolines | 1 | 2017 | 17 | 0.130 |
Why?
|
| Checklist | 1 | 2017 | 17 | 0.130 |
Why?
|
| Tomography | 1 | 2016 | 9 | 0.130 |
Why?
|
| Nerve Tissue Proteins | 1 | 2019 | 386 | 0.130 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2016 | 22 | 0.130 |
Why?
|
| Darier Disease | 1 | 2016 | 1 | 0.130 |
Why?
|
| Blood Vessels | 1 | 2016 | 36 | 0.130 |
Why?
|
| Tissue Distribution | 2 | 2010 | 240 | 0.130 |
Why?
|
| Young Adult | 7 | 2024 | 5080 | 0.120 |
Why?
|
| Bronchial Spasm | 1 | 2016 | 2 | 0.120 |
Why?
|
| Tropanes | 1 | 2016 | 7 | 0.120 |
Why?
|
| Keratosis, Seborrheic | 1 | 2016 | 2 | 0.120 |
Why?
|
| Bone and Bones | 1 | 2017 | 114 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 440 | 0.120 |
Why?
|
| Equipment Failure Analysis | 1 | 2015 | 45 | 0.120 |
Why?
|
| Aging | 1 | 2021 | 783 | 0.120 |
Why?
|
| Nuclear Family | 1 | 2015 | 13 | 0.120 |
Why?
|
| Inflammation | 1 | 2021 | 758 | 0.120 |
Why?
|
| Prevalence | 4 | 2023 | 1612 | 0.120 |
Why?
|
| Guinea Pigs | 1 | 2015 | 143 | 0.120 |
Why?
|
| Drug Carriers | 2 | 2014 | 174 | 0.120 |
Why?
|
| Cholesterol | 1 | 2016 | 232 | 0.110 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 665 | 0.110 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 81 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2019 | 863 | 0.110 |
Why?
|
| Thyroid Gland | 2 | 2024 | 23 | 0.110 |
Why?
|
| Cerebrovascular Circulation | 1 | 2014 | 70 | 0.110 |
Why?
|
| Stomach Neoplasms | 1 | 2017 | 241 | 0.110 |
Why?
|
| Prognosis | 4 | 2017 | 861 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2019 | 502 | 0.110 |
Why?
|
| Kidney | 1 | 2016 | 372 | 0.110 |
Why?
|
| Colloids | 1 | 2014 | 15 | 0.100 |
Why?
|
| Anisotropy | 1 | 2014 | 33 | 0.100 |
Why?
|
| Shear Strength | 1 | 2014 | 25 | 0.100 |
Why?
|
| Thyrotropin | 2 | 2024 | 24 | 0.100 |
Why?
|
| Brain Chemistry | 1 | 2014 | 141 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 228 | 0.100 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 167 | 0.100 |
Why?
|
| Rats, Wistar | 1 | 2014 | 283 | 0.100 |
Why?
|
| Discriminant Analysis | 1 | 2013 | 25 | 0.100 |
Why?
|
| Least-Squares Analysis | 1 | 2013 | 45 | 0.100 |
Why?
|
| Stress, Mechanical | 1 | 2014 | 164 | 0.100 |
Why?
|
| Neuroma, Acoustic | 1 | 2012 | 2 | 0.100 |
Why?
|
| Pituitary Neoplasms | 1 | 2012 | 5 | 0.100 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2012 | 3 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 1 | 2015 | 218 | 0.100 |
Why?
|
| Early Detection of Cancer | 2 | 2017 | 449 | 0.100 |
Why?
|
| Image Enhancement | 1 | 2012 | 37 | 0.090 |
Why?
|
| Thermal Conductivity | 1 | 2011 | 1 | 0.090 |
Why?
|
| Quartz | 1 | 2011 | 3 | 0.090 |
Why?
|
| Aluminum Oxide | 1 | 2011 | 11 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 125 | 0.090 |
Why?
|
| Diamond | 1 | 2011 | 9 | 0.090 |
Why?
|
| Tensile Strength | 1 | 2011 | 27 | 0.090 |
Why?
|
| Dehydration | 1 | 2011 | 23 | 0.090 |
Why?
|
| Fluorometry | 1 | 2011 | 17 | 0.090 |
Why?
|
| Silicon Dioxide | 1 | 2011 | 39 | 0.090 |
Why?
|
| Glioblastoma | 1 | 2012 | 74 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 1596 | 0.090 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 277 | 0.090 |
Why?
|
| Lasers, Semiconductor | 1 | 2011 | 1 | 0.090 |
Why?
|
| Terahertz Imaging | 1 | 2011 | 1 | 0.090 |
Why?
|
| Ovarian Neoplasms | 1 | 2015 | 415 | 0.090 |
Why?
|
| Lasers, Gas | 1 | 2011 | 3 | 0.090 |
Why?
|
| Electrons | 1 | 2011 | 76 | 0.090 |
Why?
|
| Computer Simulation | 1 | 2013 | 408 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2011 | 195 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 760 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 495 | 0.080 |
Why?
|
| Proteins | 1 | 2013 | 382 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2014 | 1766 | 0.080 |
Why?
|
| Arm | 2 | 2019 | 28 | 0.070 |
Why?
|
| Hyphae | 2 | 2019 | 36 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2023 | 934 | 0.070 |
Why?
|
| Extremities | 2 | 2019 | 20 | 0.070 |
Why?
|
| Comorbidity | 2 | 2021 | 737 | 0.070 |
Why?
|
| Adolescent | 4 | 2020 | 6081 | 0.070 |
Why?
|
| Antifungal Agents | 2 | 2019 | 169 | 0.070 |
Why?
|
| Adenosine Monophosphate | 1 | 2025 | 9 | 0.060 |
Why?
|
| Alanine | 1 | 2025 | 34 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 1067 | 0.060 |
Why?
|
| Thyroid Function Tests | 1 | 2024 | 7 | 0.050 |
Why?
|
| Hypothyroidism | 1 | 2024 | 26 | 0.050 |
Why?
|
| Keratolytic Agents | 1 | 2023 | 3 | 0.050 |
Why?
|
| Curettage | 1 | 2023 | 3 | 0.050 |
Why?
|
| 3-Hydroxybutyric Acid | 1 | 2003 | 4 | 0.050 |
Why?
|
| Siderophores | 1 | 2003 | 15 | 0.050 |
Why?
|
| Photosensitizing Agents | 1 | 2023 | 56 | 0.050 |
Why?
|
| Culture Media | 1 | 2003 | 96 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2025 | 195 | 0.050 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2023 | 13 | 0.050 |
Why?
|
| Feces | 1 | 2023 | 132 | 0.050 |
Why?
|
| Intestinal Mucosa | 1 | 2024 | 134 | 0.050 |
Why?
|
| Lens, Crystalline | 1 | 2003 | 39 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 167 | 0.050 |
Why?
|
| Galectin 1 | 1 | 2022 | 2 | 0.050 |
Why?
|
| Cornea | 1 | 2003 | 70 | 0.050 |
Why?
|
| Species Specificity | 1 | 2003 | 286 | 0.050 |
Why?
|
| Amino Acids | 1 | 2022 | 148 | 0.050 |
Why?
|
| Liver Function Tests | 1 | 2021 | 19 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 153 | 0.040 |
Why?
|
| Iron | 1 | 2003 | 251 | 0.040 |
Why?
|
| Timolol | 1 | 2021 | 3 | 0.040 |
Why?
|
| Propranolol | 1 | 2021 | 18 | 0.040 |
Why?
|
| Potassium Compounds | 1 | 2020 | 4 | 0.040 |
Why?
|
| Medical Illustration | 1 | 2020 | 2 | 0.040 |
Why?
|
| Hydroxides | 1 | 2020 | 9 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2021 | 54 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2020 | 21 | 0.040 |
Why?
|
| Alopecia | 1 | 2020 | 11 | 0.040 |
Why?
|
| Pain | 1 | 2023 | 290 | 0.040 |
Why?
|
| Caspase 3 | 1 | 2021 | 227 | 0.040 |
Why?
|
| Syndrome | 1 | 2020 | 73 | 0.040 |
Why?
|
| Pruritus | 1 | 2020 | 4 | 0.040 |
Why?
|
| Hair | 1 | 2020 | 38 | 0.040 |
Why?
|
| Epidermophyton | 1 | 2020 | 1 | 0.040 |
Why?
|
| Photography | 1 | 2020 | 50 | 0.040 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2020 | 81 | 0.040 |
Why?
|
| European Union | 1 | 2019 | 6 | 0.040 |
Why?
|
| Thalassemia | 1 | 2019 | 3 | 0.040 |
Why?
|
| Blood Component Transfusion | 1 | 2019 | 4 | 0.040 |
Why?
|
| Dacarbazine | 1 | 2019 | 6 | 0.040 |
Why?
|
| Vinblastine | 1 | 2019 | 9 | 0.040 |
Why?
|
| Blood Component Removal | 1 | 2019 | 5 | 0.040 |
Why?
|
| Pemphigus | 1 | 2019 | 1 | 0.040 |
Why?
|
| Bleomycin | 1 | 2019 | 20 | 0.040 |
Why?
|
| Suppuration | 1 | 2019 | 3 | 0.040 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2019 | 7 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 183 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2021 | 187 | 0.040 |
Why?
|
| PUVA Therapy | 1 | 2019 | 1 | 0.040 |
Why?
|
| International Cooperation | 1 | 2019 | 52 | 0.040 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 18 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2021 | 694 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 147 | 0.040 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2019 | 3 | 0.040 |
Why?
|
| Mohs Surgery | 1 | 2019 | 2 | 0.040 |
Why?
|
| Foot | 1 | 2019 | 10 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 95 | 0.040 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 38 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 59 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2022 | 329 | 0.040 |
Why?
|
| Lymphoma | 1 | 2019 | 41 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2019 | 64 | 0.040 |
Why?
|
| Microglia | 1 | 2021 | 208 | 0.040 |
Why?
|
| Eczema | 1 | 2018 | 5 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2019 | 97 | 0.040 |
Why?
|
| Diabetic Foot | 1 | 2018 | 6 | 0.040 |
Why?
|
| Granuloma, Pyogenic | 1 | 2018 | 2 | 0.040 |
Why?
|
| Port-Wine Stain | 1 | 2018 | 2 | 0.040 |
Why?
|
| Purpura | 1 | 2018 | 3 | 0.040 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 40 | 0.040 |
Why?
|
| Risk Factors | 2 | 2017 | 3994 | 0.040 |
Why?
|
| Keratinocytes | 1 | 2018 | 67 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 260 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1124 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2021 | 358 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 173 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2019 | 587 | 0.030 |
Why?
|
| Biological Products | 1 | 2019 | 91 | 0.030 |
Why?
|
| Decision Trees | 1 | 2017 | 22 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 719 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2022 | 968 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 1009 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2022 | 1455 | 0.030 |
Why?
|
| Muscarinic Antagonists | 1 | 2016 | 11 | 0.030 |
Why?
|
| Emphysema | 1 | 2016 | 6 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 423 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2016 | 92 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 355 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2017 | 142 | 0.030 |
Why?
|
| Bronchitis, Chronic | 1 | 2016 | 16 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2018 | 526 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 306 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2018 | 403 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 734 | 0.030 |
Why?
|
| Papillomavirus Infections | 1 | 2019 | 376 | 0.030 |
Why?
|
| Automation | 1 | 2014 | 22 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2014 | 55 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 129 | 0.030 |
Why?
|
| Apoptosis | 1 | 2021 | 1568 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2017 | 380 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 701 | 0.020 |
Why?
|
| Mass Screening | 1 | 2017 | 541 | 0.020 |
Why?
|
| Kinetics | 1 | 2014 | 695 | 0.020 |
Why?
|
| Pregnancy | 1 | 2017 | 1772 | 0.020 |
Why?
|
| Quality of Life | 1 | 2016 | 616 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2014 | 434 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 587 | 0.020 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2004 | 3 | 0.010 |
Why?
|